Literature DB >> 24904092

Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

María V Irazabal1, Laureano J Rangel2, Eric J Bergstralh2, Sara L Osborn1, Amber J Harmon1, Jamie L Sundsbak1, Kyongtae T Bae3, Arlene B Chapman4, Jared J Grantham5, Michal Mrug6, Marie C Hogan1, Ziad M El-Zoghby1, Peter C Harris1, Bradley J Erickson7, Bernard F King7, Vicente E Torres8.   

Abstract

The rate of renal disease progression varies widely among patients with autosomal dominant polycystic kidney disease (ADPKD), necessitating optimal patient selection for enrollment into clinical trials. Patients from the Mayo Clinic Translational PKD Center with ADPKD (n=590) with computed tomography/magnetic resonance images and three or more eGFR measurements over ≥6 months were classified radiologically as typical (n=538) or atypical (n=52). Total kidney volume (TKV) was measured using stereology (TKVs) and ellipsoid equation (TKVe). Typical patients were randomly partitioned into development and internal validation sets and subclassified according to height-adjusted TKV (HtTKV) ranges for age (1A-1E, in increasing order). Consortium for Radiologic Imaging Study of PKD (CRISP) participants (n=173) were used for external validation. TKVe correlated strongly with TKVs, without systematic underestimation or overestimation. A longitudinal mixed regression model to predict eGFR decline showed that log2HtTKV and age significantly interacted with time in typical patients, but not in atypical patients. When 1A-1E classifications were used instead of log2HtTKV, eGFR slopes were significantly different among subclasses and, except for 1A, different from those in healthy kidney donors. The equation derived from the development set predicted eGFR in both validation sets. The frequency of ESRD at 10 years increased from subclass 1A (2.4%) to 1E (66.9%) in the Mayo cohort and from 1C (2.2%) to 1E (22.3%) in the younger CRISP cohort. Class and subclass designations were stable. An easily applied classification of ADPKD based on HtTKV and age should optimize patient selection for enrollment into clinical trials and for treatment when one becomes available.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  ADPKD; cystic kidney; kidney volume; polycystic kidney disease; progression of chronic renal failure; survival

Mesh:

Year:  2014        PMID: 24904092      PMCID: PMC4279733          DOI: 10.1681/ASN.2013101138

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  32 in total

Review 1.  Determinants of renal disease variability in ADPKD.

Authors:  Peter C Harris; Sandro Rossetti
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

Review 2.  Analysis of longitudinal data: random coefficient regression modelling.

Authors:  C M Rutter; R M Elashoff
Journal:  Stat Med       Date:  1994-06-30       Impact factor: 2.373

Review 3.  Imaging for the prognosis of autosomal dominant polycystic kidney disease.

Authors:  Kyongtae T Bae; Jared J Grantham
Journal:  Nat Rev Nephrol       Date:  2010-02       Impact factor: 28.314

4.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237

5.  Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors.

Authors:  Emilio D Poggio; Andrew D Rule; Roberto Tanchanco; Susana Arrigain; Robert S Butler; Titte Srinivas; Brian R Stephany; Kathryn H Meyer; Saul Nurko; Richard A Fatica; Daniel A Shoskes; Venkatesh Krishnamurthi; David A Goldfarb; Inderbir Gill; Martin J Schreiber
Journal:  Kidney Int       Date:  2009-02-11       Impact factor: 10.612

6.  Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.

Authors:  Arlene B Chapman; Lisa M Guay-Woodford; Jared J Grantham; Vicente E Torres; Kyongtae T Bae; Deborah A Baumgarten; Philip J Kenney; Bernard F King; James F Glockner; Louis H Wetzel; Marijn E Brummer; W Charles O'Neill; Michelle L Robbin; William M Bennett; Saulo Klahr; Gladys H Hirschman; Paul L Kimmel; Paul A Thompson; J Philip Miller
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

7.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

Authors:  Loes van Keimpema; Frederik Nevens; Ragna Vanslembrouck; Martijn G H van Oijen; Aswin L Hoffmann; Helena M Dekker; Robert A de Man; Joost P H Drenth
Journal:  Gastroenterology       Date:  2009-07-29       Impact factor: 22.682

8.  Unified criteria for ultrasonographic diagnosis of ADPKD.

Authors:  York Pei; James Obaji; Annie Dupuis; Andrew D Paterson; Riccardo Magistroni; Elizabeth Dicks; Patrick Parfrey; Benvon Cramer; Eliecer Coto; Roser Torra; Jose L San Millan; Robert Gibson; Martijn Breuning; Dorien Peters; David Ravine
Journal:  J Am Soc Nephrol       Date:  2008-10-22       Impact factor: 10.121

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease.

Authors:  Sandro Rossetti; Vickie J Kubly; Mark B Consugar; Katharina Hopp; Sushmita Roy; Sharon W Horsley; Dominique Chauveau; Lesley Rees; T Martin Barratt; William G van't Hoff; Patrick Niaudet; W Patrick Niaudet; Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-01-21       Impact factor: 10.612

View more
  195 in total

1.  Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.

Authors:  Matteo Bargagli; Nasser A Dhayat; Manuel Anderegg; Mariam Semmo; Uyen Huynh-Do; Bruno Vogt; Pietro Manuel Ferraro; Daniel G Fuster
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 8.237

2.  Multiple unilateral subcapsular cortical hemorrhagic cystic disease of the kidney: CT and MRI findings and clinical characteristic.

Authors:  Kotaro Yoshida; Naoki Takahashi; Bernard F King; Akira Kawashima; Peter C Harris; Lynn D Cornell; Emilie Cornec-Le Gall; Dai Inoue; Ichiro Mizushima; Mitsuhiro Kawano; Eric Thervet; Paul René de Cotret; Vicente E Torres
Journal:  Eur Radiol       Date:  2019-02-26       Impact factor: 5.315

3.  The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Emilie Cornec-Le Gall; Marie-Pierre Audrézet; Annick Rousseau; Maryvonne Hourmant; Eric Renaudineau; Christophe Charasse; Marie-Pascale Morin; Marie-Christine Moal; Jacques Dantal; Bassem Wehbe; Régine Perrichot; Thierry Frouget; Cécile Vigneau; Jérôme Potier; Philippe Jousset; Marie-Paule Guillodo; Pascale Siohan; Nazim Terki; Théophile Sawadogo; Didier Legrand; Victorio Menoyo-Calonge; Seddik Benarbia; Dominique Besnier; Hélène Longuet; Claude Férec; Yannick Le Meur
Journal:  J Am Soc Nephrol       Date:  2015-07-06       Impact factor: 10.121

4.  Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Authors:  Godela M Brosnahan; Kaleab Z Abebe; Charity G Moore; Frederic F Rahbari-Oskoui; Kyongtae T Bae; Jared J Grantham; Robert W Schrier; William E Braun; Arlene B Chapman; Michael F Flessner; Peter C Harris; Marie C Hogan; Ronald D Perrone; Dana C Miskulin; Theodore I Steinman; Vicente E Torres
Journal:  Am J Kidney Dis       Date:  2018-01-03       Impact factor: 8.860

5.  3DUS as an alternative to MRI for measuring renal volume in children with autosomal dominant polycystic kidney disease.

Authors:  Luc Breysem; Stéphanie De Rechter; Frederik De Keyzer; Maria Helena Smet; Bert Bammens; Maria Van Dyck; Maarten Hofmans; Raymond Oyen; Elena Levtchenko; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2018-01-06       Impact factor: 3.714

6.  Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease.

Authors:  Katharina Hopp; Emilie Cornec-Le Gall; Sarah R Senum; Iris B A W Te Paske; Sonam Raj; Sravanthi Lavu; Saurabh Baheti; Marie E Edwards; Charles D Madsen; Christina M Heyer; Albert C M Ong; Kyongtae T Bae; Richard Fatica; Theodore I Steinman; Arlene B Chapman; Berenice Gitomer; Ronald D Perrone; Frederic F Rahbari-Oskoui; Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2019-10-09       Impact factor: 10.612

Review 7.  The Treatment of Autosomal Dominant Polycystic Kidney Disease.

Authors:  Wolfgang E Kühn; Gerd Walz
Journal:  Dtsch Arztebl Int       Date:  2015-12-21       Impact factor: 5.594

8.  Volume regression of native polycystic kidneys after renal transplantation.

Authors:  Yeonsoon Jung; María V Irazabal; Fouad T Chebib; Peter C Harris; Patrick G Dean; Mikel Prieto; Fernando G Cosio; Ziad M El-Zoghby; Vicente E Torres
Journal:  Nephrol Dial Transplant       Date:  2015-06-04       Impact factor: 5.992

Review 9.  The importance of total kidney volume in evaluating progression of polycystic kidney disease.

Authors:  Jared J Grantham; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

10.  Polycystic kidney disease: Kidney volume--a crystal ball for ADPKD prognosis?

Authors:  Emilie Cornec-Le Gall; Yannick Le Meur
Journal:  Nat Rev Nephrol       Date:  2014-08-05       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.